Effects of Empagliflozin on Right Ventricular Function in Heart Failure with Reduced Ejection Fraction Results from the Empire HF trial

ObjectivesTo investigate the effect of empagliflozin on right ventricular (RV) function in patients with HFrEF. BackgroundSodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes and reverse left ventricle (LV) remodeling in heart failure with reduced ejection fraction (HFrEF). The impact on RV function remains uncertain. MethodsThe Empire HF trial was a randomized, double-blind trial of 190 participants with HFrEF (LVEF [≤]40%) randomized (1:1) to empagliflozin (10mg/daily) or matching placebo for 12 weeks. The primary endpoint was changes in RV free wall strain (RVFWS) across the whole cohort. RVFWS was also stratified into tertiles based on baseline RVFWS. Secondary endpoints included changes in TAPSE and RV S velocity. ResultsBaseline characteristics were balanced between the groups (mean age of 64{+/-}11 years, 86% male, mean LVEF 29{+/-}8%, 79% in NYHA class II). The overall mean RVFWS was -16.7{+/-}6.1%, with the empagliflozin group at -16.4{+/-}6.2% and the placebo group at -16.9{+/-}5.9%. No differences were observed in RVFWS between the groups. When stratified by baseline RVFWS into tertiles, patients in the lowest tertile demonstrated a significant improvement with empagliflozin (treatment effect: -2.9% [95% CI: -5.0 to -0.3]; P=0.027), independent of LVEF, plasma volume, or weight loss changes. No significant treatment effect was observed in the middle or highest tertiles of RVFWS, nor in the overall or lowest tertiles of TAPSE or RV S. ConclusionsEmpagliflozin exerted no overall effect on RV function in stable HFrEF patients, but significantly improved RVFWS in patients in the lowest tertile of RVFWS after 12 weeks of treatment. Trial RegistrationClinicalTrials.gov, Unique Identifier: NCT03198585